September 24, 2014 1:14 AM ET

Biotechnology

Company Overview of The Translational Genomics Research Institute

Company Overview

The Translational Genomics Research Institute develops earlier diagnostics and treatments. It develops diagnostics, prognostics, and therapies for cancer, neurological disorders, diabetes, and other complex diseases. The company also provides bio4d to offer tools for managing various aspects of the biospecimen lifecycle, including related data enabling clinical genomics data warehouse capabilities for data mining and integrative analysis for the discovery or validation of biomarkers, diagnostics, and therapeutics. In addition, The Translational Genomics Research Institute offers genome technology and core services; genome technology for performing contemporary genetic analysis to benefit the...

445 North Fifth Street

Phoenix, AZ 85004

United States

Founded in 2002

Phone:

602-343-8400

Fax:

602-343-8440

Key Executives for The Translational Genomics Research Institute

Chief Financial Officer
Chief Operating Officer and President of TGen Accelerators
President of TGen Foundation
Executive Vice President and Physician-In-Chief
Age: 66
Compensation as of Fiscal Year 2014.

The Translational Genomics Research Institute Key Developments

the Translational Genomics Research Institute and Ceres Nanosciences, Inc. Collaboration to Develop High-Throughput Nanotrap Enrichment Methods for Mass Spectrometry

The Translational Genomics Research Institute and Ceres Nanosciences Inc. announced a development collaboration to benefit patients with cancer, infectious diseases, and other life-threatening illnesses. TGen to uncover the underlying molecular causes of disease, as well as developing automated workflows to enable molecular medicine. Ceres, a biotechnology company located in northern Virginia, has developed and commercialized a novel nanotechnology, the "Nanotrap", which provides powerful sample processing capabilities for a wide array of diagnostic applications and sample handling needs. The Nanotrap technology was invented at George Mason University (Mason) under funding from the National Institutes of Health (NIH) for biomarker discovery applications, and currently is being developed into commercial grade products by Ceres with continuing support from NIH, Defense Advanced Research Projects Agency, Department of Homeland Security (DHS), and the Commonwealth of Virginia. The combination of Ceres' Nanotrap technology and TGen's world-class research capabilities and resources will lead to significant improvements in high sensitivity and high throughput clinical diagnostics, providing substantial patient benefit with newer, more accurate, and more reliable testing methods for a range of life-threatening diseases. Ceres, TGen and Mason will use the exciting preliminary results to seek additional collaborations and support to develop an array of new sample processing and diagnostic solutions.

The Translational Genomics Research Institute and Easton-Bell Sports, Inc Announce Partnership for Biomarker Study of Concussive Injuries

The Translational Genomics Research Institute (TGen), and Easton-Bell Sports, Inc. through its Riddell brand, announced they would work together on a study designed to advance athlete concussion detection and treatment. Information gathered through the study will also be used to develop new football headgear and further refine updates to player monitoring technology. The genesis of this potentially study is to merge a player's genetic information with real-time microelectronic information captured by Riddell's Sideline Response System (SRS). A highly sophisticated, data-intensive system, Riddell SRS provides researchers, athletic staff and players with a wide range of valuable information on the number and severity of head impacts a player receives during games and practices. Employed since 2003 by several well-respected research institutions, Riddell SRS has captured 1.8 million impacts from youth to elite football competition, and its data has led to impactful changes to rules, how the game is played and coached, and has informed new helmet designs. While the joint study will begin with football, the Riddell-TGen partnership has the potential to improve sports equipment manufactured by brands in the broader Easton-Bell Sports portfolio, including headgear for hockey, baseball, cycling, snowsports, and powersports. As part of the study, TGen will work with the Barrow Neurological Institute whose B.R.A.I.N.S. (Barrow Resource for Acquired Injury to the Nervous System) program treats patients who have sustained a traumatic brain or spinal cord injury.

Scottsdale Healthcare Corp. and The Translational Genomics Research Institute Demonstrate Study of New Drug Regimen for Patients with Pancreatic Cancer

A new cancer drug combination demonstrated significant improvement in overall survival of late-stage pancreatic cancer patients compared to those receiving standard treatment, according to results of a Phase III clinical trial led by physicians from Scottsdale Healthcare Corp.'s Virginia G. Cancer Center Clinical Trials, a partnership with The Translational Genomics Research Institute. Physicians at the Virginia G. Piper Cancer Center at Scottsdale Healthcare were first to design a clinical trial to determine the safety, tolerability and effectiveness of nab-paclitaxel (Abraxane) in combination with the standard drug gemcitabine in patients with advanced pancreatic cancer. Full results are expected to be presented at the American Society of Clinical Oncology (ASCO) 2013 Gastrointestinal Cancers Symposium in Jan. 24-26 in San Francisco. The pancreas is a gland behind the stomach that secretes enzymes into the upper part of the small intestine to help digestion. It also produces hormones, including insulin, which helps regulate the metabolism of sugars. Advanced pancreatic cancer is fourth most common cause of cancer death in the United States and throughout the world. It is a difficult to diagnose and treat cancer with the lowest survival rates among all cancer types.

Similar Private Companies By Industry

Company Name Region
Agradis, Inc. United States
Anagen Therapeutics, Inc. United States
Targetech Inc. United States
BIO Wellness, Inc. United States
Ciclofilin Pharmaceuticals Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact The Translational Genomics Research Institute, please visit www.tgen.org. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.